[CAS NO. 890056-27-6] Custirsen

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [890056-27-6]

Catelog

HY-143230

Brand

MCE

CAS

890056-27-6

DESCRIPTION [890056-27-6]

Overview

MDL	-
Molecular Weight	7346.00
Molecular Formula	-
SMILES	[Custirsen]

For research use only. We do not sell to patients.

Summary

Custirsen is a highly specific antisense oligonucleotide that inhibits the production of clusterin , an antiapoptotic protein that is upregulated in response to chemotherapy and that confers treatment resistance.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00258375	NCIC Clinical Trials Group\|Canadian Cancer Trials Group	Breast Cancer	October 21, 2005	Phase 2
NCT01630733	Achieve Life Sciences	Non-Small Cell Lung Cancer	September 2012	Phase 3
NCT01188187	Achieve Life Sciences\|Teva Branded Pharmaceutical Products R&D, Inc.	Prostate Cancer	November 2010	Phase 3
NCT00138658	Achieve Life Sciences	Non-small Cell Lung Cancer	November 2004	Phase 1\|Phase 2
NCT01578655	Achieve Life Sciences	Prostate Cancer	August 2012	Phase 3
NCT00471432	NCIC Clinical Trials Group\|Canadian Cancer Trials Group	Bladder Cancer\|Breast Cancer\|Kidney Cancer\|Lung Cancer\|Ovarian Cancer\|Prostate Cancer\|Unspecified Adult Solid Tumor, Protocol Specific	April 4, 2003	Phase 1
NCT00258388	NCIC Clinical Trials Group\|Canadian Cancer Trials Group	Prostate Cancer	September 28, 2005	Phase 2
NCT00327340	Achieve Life Sciences	Prostate Cancer	July 2006	Phase 2
NCT01083615	Achieve Life Sciences\|Teva Pharmaceuticals USA	Castrate-Resistant Prostate Cancer\|Hormone Refractory Prostate Cancer	March 2010	Phase 3
NCT00054106	NCIC Clinical Trials Group\|Canadian Cancer Trials Group	Prostate Cancer	December 10, 2002	Phase 1
NCT01874561	Achieve Life Sciences\|Teva Branded Pharmaceutical Products R&D, Inc.	Cardiac Conduction and Repolarization	May 2013	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 50 mg/mL ( 6.81 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.1361 mL	0.6806 mL	1.3613 mL
5 mM	0.0272 mL	0.1361 mL	0.2723 mL
10 mM	---	---	---

* Please refer to the solubility information to select the appropriate solvent.

References

[1] Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005;97(17):1287-1296.